455,835 Shares in enGene Holdings Inc. $ENGN Purchased by Eversept Partners LP

Eversept Partners LP acquired a new position in enGene Holdings Inc. (NASDAQ:ENGN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 455,835 shares of the company’s stock, valued at approximately $4,116,000. Eversept Partners LP owned approximately 0.68% of enGene at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Cresset Asset Management LLC purchased a new stake in enGene in the 2nd quarter worth about $36,000. Paloma Partners Management Co purchased a new stake in enGene in the 2nd quarter worth about $38,000. Raymond James Financial Inc. lifted its stake in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in enGene in the 3rd quarter worth about $76,000. Finally, PFS Partners LLC lifted its stake in enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Down 0.6%

ENGN opened at $1.74 on Thursday. enGene Holdings Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $12.25. The business has a 50-day moving average of $4.10 and a 200-day moving average of $7.10. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 11.75. The company has a market capitalization of $116.56 million, a PE ratio of -0.80 and a beta of -0.30.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, June 15th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.91. During the same period in the previous year, the company earned $0.51 EPS. Equities research analysts forecast that enGene Holdings Inc. will post -1.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ENGN shares. Leerink Partners downgraded enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target for the company. in a research note on Friday, May 8th. UBS Group cut their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. HC Wainwright cut their price target on enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday. Citigroup downgraded enGene from a “market outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Finally, Guggenheim downgraded enGene from a “buy” rating to a “neutral” rating in a research note on Thursday, May 7th. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.05.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.